2004, Number 1
PDF size: 579.00 Kb.
ABSTRACTIntroduction of new antiretroviral agents and development of new prophylaxis schedules against opportunistic microorganisms have allowed increase in survival as well as better quality of life in HIV-infected patients. These new treatment schedules have changed the epidemiology of opportunistic infections that previous to use of highly active antiretroviral therapy (HAART), fomerly occurred with high frequency in HIV-infected children. Specifically, pneumonia due to Pneumocystis carinii formerly occurred in 12 to 80% of these patients and was associated with high mortality. Currently, with use of combined antiretroviral therapy (ART) and prophylactic treatments important reduction of PCP has been observed. However, despite these benefits ART is not yet available for many patients from several developing countries who are at risk for opportunistic infections, mainly due to Pneumocystis carinii, which can affect life expectancy. Therefore, the purpose of this paper was a review of epidemiologic, clinical, and therapeutic characteristics of P. carinii pneumonia in HIVinfected children.
Simpson B, Shapiro ED, Andiman WA. Prospective cohort study of children born to human immunodeficiency virus-infected mothers, 1985 through 1997: trends in the risk of vertical transmission, mortality and acquired immunodeficiency syndrome indicator diseases in the era before highly active antiretroviral therapy. Pediatr Infect Dis J 2000;19:618-24.
American Academy of Pediatrics. Infecciones por Pneumocystis carinii. En: Pickering LK, Peter G, Baker CJ, Gerber MA, MacDonald NE, Orenstein WA Patriarca P, editors. Red Book. Enfermedades Infecciosas en Pediatría. Informe del Comité de Enfermedades Infecciosas de la American Academy of Pediatrics. Ed. Médica Panamericana;. 25ª Edición. Buenos Aires, Argentina 2001; pp. 452-456.
Principi N, Marchisio P, Onorato J, et al. Long term administration of aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia in infants and children with symptomatic human immunodeficiency virus infection. The Italian Pediatric Collaborative Study Group on Pentamidine. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:158-163.
Dankner W, Yogev R, Hughes W, Xu J. The Pediatric ACTG 254 Team. Phase ll/lll, randomized, double-blind trial to compare atovaquone plus azithromycin to TMP/SMX in the prevention of multiple opportunistic pathogen infections (MOPPS) in HIV-infected children. Program and Abstract of Advancing Children´s Health 2000: A Joint Meeting of the Pediatric Academic Societies and the American Academy of Pediatric; May 12-16, 2000; Boston, MA, USA, abstract 1531.